The FDA approved Sephience - PTC's oral therapy for a rare metabolic disorder called phenylketonuria - last month, ...

The US Food and Drug Administration (FDA) has rejected PTC Therapeutics’ new drug application (NDA) for vatiquinone in ...

PTC is demonstrating robust growth and consistent profitability, and analyst sentiment has grown more favorable recently.

PTC Therapeutics yesterday revealed that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL ...

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another ...

"We are of course disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive, who noted that the FDA is seeking another 'adequate and well-controlled' ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

Morgan Stanley lowered the firm’s price target on PTC Therapeutics (PTCT) to $71 from $76 and keeps an Overweight rating on the shares after the ...

JPMorgan added PTC Therapeutics (PTCT) to the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $68 price target ...

PEG's large-load inquiry pipeline soared to 9.4 GW, with ~90% tied to data centers, underscoring a powerful multi-year growth ...